Harvard Bioscience Announces Reverse Stock Split
MWN-AI** Summary
Harvard Bioscience, Inc. (Nasdaq: HBIO), a prominent provider of life science research tools, has announced a 1-for-10 reverse stock split. This decision received the green light from the company’s stockholders during a special meeting on March 6, 2026. The reverse split will take effect at 4:30 PM Eastern Time on March 13, 2026, with trading on a post-split adjusted basis beginning on March 16, 2026.
The primary objective of the reverse stock split is to increase Harvard Bioscience's stock price, addressing compliance with Nasdaq’s minimum bid price requirement for continued listing. Under the 1-for-10 reverse split, every ten shares will convert automatically into one share, effectively decreasing the total number of outstanding shares from approximately 44.7 million to 4.47 million. However, the total authorized shares will remain unchanged.
For stockholders, no action is necessary to receive post-split shares if held electronically. Those with physical stock certificates will receive instructions from the company’s transfer agent, Computershare Inc., regarding the conversion or exchange of their certificates. Fractional shares that arise from the reverse split will be compensated with cash payments based on the adjusted closing stock price.
This strategic move aims to position Harvard Bioscience favorably in the market, enabling it to enhance its capital structure, reduce refinancing risks, and pursue long-term growth. The company serves a diverse clientele, including prestigious academic institutions and leading pharmaceutical companies worldwide.
As always, potential investors should consider risks associated with forward-looking statements made by the company concerning its market position and compliance efforts as outlined in their filings with the SEC. For further inquiries, investor relations are available through CFO Mark Frost.
MWN-AI** Analysis
Harvard Bioscience’s recent announcement of a 1-for-10 reverse stock split, effective March 13, 2026, raises significant considerations for investors. The primary objective of this maneuver is to elevate the stock price to meet Nasdaq's minimum bid compliance requirement, a marker of the company's recent struggles.
From a market perspective, reverse stock splits can be seen as a double-edged sword. On one hand, they can restore investor confidence and attract institutional interest by preventing delisting, which could lead to improved liquidity and stability in the share price post-split. However, they could also signal underlying issues in the company's performance, as a declining stock price often reflects investor doubts about future growth and profitability.
For investors considering entry or exit points around this event, it’s essential to analyze the historical context of Harvard Bioscience. The company operates in a competitive sector focused on life science research tools, facing pressures from both established players and emerging biotech firms. Therefore, while a successful split might stabilize the stock price temporarily, the long-term viability of an investment will depend heavily on the company's ability to innovate and maintain sales momentum post-split.
Investors should keep an eye on the market’s reaction to the split, including trading volume and share price movements. A strong positive response could indicate renewed investor confidence, while a muted or negative reaction might suggest ongoing concerns about the company’s operational fundamentals.
Additionally, stakeholders should closely monitor board decisions, earnings announcements, and any strategic partnerships or product launches following the split, as these could significantly influence the company's stock performance moving forward. Overall, careful due diligence and monitoring of Harvard Bioscience's trajectory are crucial for making informed investment decisions in the wake of the reverse stock split.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Harvard Bioscience’s common stock is expected to begin trading on a post-split adjusted basis on March 16, 2026
HOLLISTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), a global leader in life science research tools, today announced that its board of directors approved the Company’s 1-for-10 reverse stock split (the “Reverse Split”) of the Company’s common stock, par value $0.01 per share. The Reverse Split was approved by the stockholders of the Company at a special meeting held on March 6, 2026.
The Reverse Split will legally take effect at 4:30 p.m. Eastern Time, on March 13, 2026. The Reverse Split is intended to increase the per share trading price of the Company’s common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.
The 1-for-10 Reverse Split will automatically convert every 10 current shares of the Company’s common stock into one share of common stock. No fractional shares will be issued in connection with the Reverse Split. Stockholders who would otherwise hold a fractional share of the Company’s common stock following the Reverse Split will receive a cash payment in lieu thereof at a price equal to that fractional share to which the stockholder would otherwise be entitled multiplied by the closing sale price of the common stock on The Nasdaq Capital Market, as adjusted for the Reverse Split, on March 13, 2026.
The Reverse Split will reduce the number of shares of outstanding common stock from approximately 44,719,894 shares, to approximately 4,471,989 shares. The total authorized number of shares will not be reduced. Proportional adjustments will also be made to the exercise and conversion prices of the Company's outstanding stock options, warrants, and convertible securities, and to the number of shares issued and issuable under the Company's stock incentive plans.
Stockholders holding their shares electronically in book-entry form are not required to take any action to receive post-split shares. Stockholders owning shares through a bank, broker, or other nominee will have their positions automatically adjusted to reflect the Reverse Split, subject to brokers' particular processes, and will not be required to take any action in connection with the Reverse Split. For those stockholders holding physical stock certificates, the Company's transfer agent, Computershare Inc., will send instructions for exchanging those certificates for shares held electronically in book-entry form or for new certificates, in either case representing the post-split number of shares, and any payments in cash in lieu of fractional shares, if applicable.
Additional information regarding the Reverse Stock Split is available in the Company's definitive proxy statement originally filed with the U.S. Securities and Exchange Commission (SEC) on January 30, 2026.
About Harvard Bioscience
Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.
For more information, please visit our website at www.harvardbioscience.com.
Forward-Looking Statements
This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend,” “believe” and similar expressions or statements that do not relate to historical matters. Forward-looking statements include, but are not limited to, statements concerning the sustainability of the Company’s ability to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market, its capital structure, its lower near-term refinancing risk and path toward long-term deleveraging, expected future financial and operational performance, the strength of the Company’s market position, business model and anticipated macroeconomic conditions, and matters relating to our ability to continue as a going concern, fund our operations, or comply with the terms of our credit agreement. Forward-looking statements do not guarantee future performance and involve known and unknown uncertainties, risks, assumptions, and contingencies, many of which are outside the Company’s control. Risks and other factors that could cause the Company’s actual results to differ materially from those described in its forward-looking statements include those described in the “Risk Factors” section of the Company’s most recently filed Annual Report on Form 10-K and the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 as filed with the Securities and Exchange Commission (“SEC”), as well as in the Company’s other filings with the SEC. Forward-looking statements are based on the Company’s expectations and assumptions as of the date of this document. Except as required by law, the Company assumes no obligation to update forward-looking statements to reflect any change in expectations, even as new information becomes available.
Harvard Bioscience Investor Inquiries:
Mark Frost
Interim Chief Financial Officer
(508) 893-3120
investors@harvardbioscience.com
FAQ**
How is Harvard Bioscience Inc. (HBIO) planning to leverage the reverse stock split to enhance its compliance with Nasdaq Capital Market listing standards, and what does this mean for investor confidence?
What strategic initiatives does Harvard Bioscience Inc. (HBIO) have in place to ensure its financial performance improves post-reverse stock split?
Given the current market conditions, what are the potential risks Harvard Bioscience Inc. (HBIO) mentions that could impact the effectiveness of the reverse stock split?
How will the reverse stock split affect Harvard Bioscience Inc. (HBIO) shareholders in terms of share value and liquidity, especially for those holding physical stock certificates?
**MWN-AI FAQ is based on asking OpenAI questions about Harvard Bioscience Inc. (NASDAQ: HBIO).
NASDAQ: HBIO
HBIO Trading
-6.26% G/L:
$0.5523 Last:
116,559 Volume:
$0.57 Open:
